The DOI matches its Crossref record; 97 of the 102 references it cites were found in a registry or an index.
Efficacy of PI3K inhibitors in advanced breast cancer
Open accessAbstract
The phosphoinositide 3 (PI3)-kinase/Akt signaling pathway has always been a focus of interest in breast cancer due to its role in cell growth, cell proliferation, cell migration and deregulated apoptosis. Its activation has been linked to endocrine resistance and worse prognosis in certain subgroups of breast cancer. In addition, deregulation of the PI3K/Akt pathway including PIK3CA activating mutation is frequently present in breast cancer. Multiple efforts have been carried out to target this pathway, initially with pan-PI3K inhibitors with some hint of activity but hampered by their limiting side-effects. A recent large randomized trial in patients with endocrine-resistant PIK3CA-mutant hormone receptor (HR)-positive tumors led to the approval of the first PI3K inhibitor, alpelisib, in combination with fulvestrant. The specificity of alpelisib against the p110α catalytic isoform provided additional efficacy and a better toxicity profile. In this review, we summarize the main research with PI3K inhibitors in breast cancer and we provide some insight of potential future combinations of this treatment in breast cancer patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Unlike p110γ and p110δ, p110α is widely expressed and exclusively activated by RAS.”
From Targeting KRAS mutant cancers: from druggable therapy to drug resistance (2022) · cites this paper as [79]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Nishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N. (2013) · Oncology · doi:10.1159/000353099 · Cited by 13,239
Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
Li, J., Yen, C., Liaw, D., Podsypanina, K., Bose, S., Wang, S. I., Puc, J., Miliaresis, C., Rodgers, L., McCombie, R., et al. (1997) · Science · doi:10.1126/science.275.5308.1943 · Cited by 4,785
The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism
Engelman, J. A., Luo, J., & Cantley, L. C. (2006) · Nature Reviews Genetics · doi:10.1038/nrg1879 · Cited by 3,330
Palbociclib and letrozole in advanced breast cancer
Finn, R. S., Martin, M., Rugo, H. S., Jones, S., Im, S.-A., Gelmon, K., Harbeck, N., Lipatov, O. N., Walshe, J. M., Moulder, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607303 · Cited by 3,007
The PI3K Pathway in Human Disease
Fruman, D. A., Chiu, H., Hopkins, B. D., Bagrodia, S., Cantley, L. C., & Abraham, R. T. (2017) · Cell · doi:10.1016/j.cell.2017.07.029 · Cited by 2,749
Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer
André, F., Ciruelos, E., Rubovszky, G., Campone, M., Loibl, S., Rugo, H. S., Iwata, H., Conte, P., Mayer, I. A., Kaufman, B., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1813904 · Cited by 2,622
Cristofanilli, M., Turner, N. C., Bondarenko, I., Ro, J., Im, S.-A., Masuda, N., Colleoni, M., DeMichele, A., Loi, S., Verma, S., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00613-0 · Cited by 1,827
The emerging mechanisms of isoform-specific PI3K signalling
Vanhaesebroeck, B., Guillermet-Guibert, J., Graupera, M., & Bilanges, B. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2882 · Cited by 1,767
Cited by
Sorted by citations
Targeting PI3K/Akt signal transduction for cancer therapy
He, Y., Sun, M., Zhang, G. G., Yang, J., Chen, K. S., Xu, W. W., & Li, B. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00828-5 · Cited by 2,045
Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer
Ye, F., Dewanjee, S., Li, Y., Jha, N. K., Chen, Z., Kumar, A., vishakha, V., Behl, T., Jha, S. K., & Tang, H. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01805-y · Cited by 619
PI3K inhibitors are finally coming of age
Vanhaesebroeck, B., Perry, M. W. D., Brown, J. R., André, F., & Okkenhaug, K. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00209-1 · Cited by 494
Activation of PI3K/AKT/mTOR Pathway Causes Drug Resistance in Breast Cancer
Dong, C., Wu, J., Chen, Y., Nie, J., & Chen, C. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.628690 · Cited by 404
Li, Y., Xu, Z., Ruan, S., Mo, S., Qin, J., & Cheng, X. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01219-0 · Cited by 330
Current State of Breast Cancer Diagnosis, Treatment, and Theranostics
Bhushan, A., Gonsalves, A., & Menon, J. U. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13050723 · Cited by 339
Targeting the PI3K/AKT/mTOR and RAF/MEK/ERK pathways for cancer therapy
Li, Q., Li, Z., Luo, T. L., & Shi, H. (2022) · Molecular Biomedicine · doi:10.1186/s43556-022-00110-2 · Cited by 299
Targeting KRAS mutant cancers: from druggable therapy to drug resistance
Zhu, C., Guan, X., Zhang, X., Luan, X., Song, Z., Cheng, X., Zhang, W., & Qin, J.-J. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01629-2 · Cited by 231
Liu, Q., & Xie, L. (2021) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1008653 · Cited by 205
PI3K/AKT/mTOR-Targeted Therapy for Breast Cancer
Zhu, K., Wu, Y. Q., He, P., Fan, Y. J., Zhong, X., Zheng, H. Y., & Luo, T. L. (2022) · Cells · doi:10.3390/cells11162508 · Cited by 197
Overview of recent advances in metastatic triple negative breast cancer
O'Reilly, D., AlSendi, M., & Kelly, C. M. (2021) · World Journal of Clinical Oncology · doi:10.5306/wjco.v12.i3.164 · Cited by 138
Resistance and Overcoming Resistance in Breast Cancer
Luque-Bolivar, A., Pérez-Mora, E., Villegas, V. E., & Rondón‐Lagos, M. (2020) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s270799 · Cited by 139
Fusco, N., Malapelle, U., Fassan, M., Marchiò, C., Buglioni, S., Zupo, S., Criscitiello, C., Vigneri, P. G., Tos, A. P. D., Maiorano, E., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.644737 · Cited by 124
Drugging the PI3K/AKT/mTOR Pathway in ER+ Breast Cancer
Alves, C. L., & Ditzel, H. J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054522 · Cited by 126
Lu, Y., & Liu, W. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00913 · Cited by 119
RAS signaling in carcinogenesis, cancer therapy and resistance mechanisms
Yang, X., & Wu, H. K. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01631-9 · Cited by 133
HER-2-Targeted Nanoparticles for Breast Cancer Diagnosis and Treatment
Sitia, L., Sevieri, M., Signati, L., Bonizzi, A., Chesi, A., Mainini, F., Corsi, F., & Mazzucchelli, S. (2022) · Cancers · doi:10.3390/cancers14102424 · Cited by 122
Targeting the Estrogen Receptor for the Treatment of Breast Cancer: Recent Advances and Challenges
Rej, R. K., Thomas, J. E., Acharyya, R. K., Rae, J. M., & Wang, S. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00136 · Cited by 117
Traditional Chinese Medicine for adjuvant treatment of breast cancer: Taohong Siwu Decoction
Jiang, H., Li, M., Du, K., Ma, C., Cheng, Y., Wang, S., Nie, X., Fu, C., & He, Y. (2021) · Chinese Medicine · doi:10.1186/s13020-021-00539-7 · Cited by 112
Fine-Tuning Cardiac Insulin-Like Growth Factor 1 Receptor Signaling to Promote Health and Longevity
Abdellatif, M., Trummer-Herbst, V., Heberle, A. M., Humnig, A., Pendl, T., Durand, S., Cerrato, G., Hofer, S. J., Islam, M., Voglhuber, J., et al. (2022) · Circulation · doi:10.1161/circulationaha.122.059863 · Cited by 108
Hepatocellular carcinoma: signaling pathways, targeted therapy, and immunotherapy
Luo, X., He, X., Zhang, X., Zhao, X., Zhang, Y., Shi, Y., & Hua, S. (2024) · MedComm · doi:10.1002/mco2.474 · Cited by 115
Yao, X., Li, W., Li, L., Li, M., Zhao, Y., Fang, D., Zeng, X., & Luo, Z. Y. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-04711-1 · Cited by 101
Zeng, X., Shi, G., He, Q., & Zhu, P. (2021) · Scientific Reports · doi:10.1038/s41598-021-00268-9 · Cited by 78
Petri, B. J., Piell, K. M., Whitt, G. C. S., Wilt, A. E., Poulton, C. C., Lehman, N. L., Clem, B. F., Nystoriak, M. A., Wysoczynski, M., & Klinge, C. M. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.07.015 · Cited by 67
Covalent Proximity Scanning of a Distal Cysteine to Target PI3Kα
Borsari, C., Keleş, E., McPhail, J. A., Schäfer, A., Sriramaratnam, R., Goch, W., Schaefer, T., Pascale, M. D., Bal, W., Gstaiger, M., et al. (2022) · Journal of the American Chemical Society · doi:10.1021/jacs.1c13568 · Cited by 65
Rasti, A. R., Guimarães-Young, A., Datko, F. M., Borges, V. F., Aisner, D. L., & Shagisultanova, E. I. (2022) · JCO Precision Oncology · doi:10.1200/po.21.00370 · Cited by 66
Predictive, preventive, and personalized medicine in breast cancer: targeting the PI3K pathway
Tufail, M., Hu, J.-J., Liang, J., He, C., Wan, W., Huang, Y., Jiang, C., Wu, H., & Li, N. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-023-04841-w · Cited by 65
Highlights on U.S. FDA-approved halogen-containing drugs in 2024
Ali, S., Tian, X., Meccia, S. A., & Zhou, J. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117380 · Cited by 63
Cellular Mechanisms of Circulating Tumor Cells During Breast Cancer Metastasis
Park, H., Brown, S. R., & Kim, Y. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21145040 · Cited by 57
Unbiased Detection of Driver Mutations in Extramammary Paget Disease
Ishida, Y., Kakiuchi, N., Yoshida, K., Inoue, Y., Irie, H., Kataoka, T. R., Hirata, M., Funakoshi, T., Matsushita, S., Hata, H., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3205 · Cited by 55
Fuso, P., Muratore, M., D’Angelo, T., Paris, I., Carbognin, L., Tiberi, G., Pavese, F., Duranti, S., Orlandi, A., Tortora, G., et al. (2022) · Cancers · doi:10.3390/cancers14092161 · Cited by 55
Xiao, W., Zhang, G., Chen, B., Chen, X., Wen, L., Lai, J., Li, X., Li, M., Liu, H., Liu, J. L., et al. (2021) · Journal of Cancer · doi:10.7150/jca.52993 · Cited by 53
Miranda, F., Prazeres, H., Mendes, F., Martins, D. F., & Schmitt, F. C. (2021) · Molecular Biology Reports · doi:10.1007/s11033-021-06863-3 · Cited by 56
The Importance of Phosphoinositide 3-Kinase in Neuroinflammation
Wright, B., King, S. P., & Suphioglu, C. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252111638 · Cited by 55
PI3K inhibition in breast cancer: Identifying and overcoming different flavors of resistance
Vitale, S. R., Martorana, F., Stella, S., Motta, G., Inzerilli, N., Massimino, M., Tirrò, E., Manzella, L., & Vigneri, P. G. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103334 · Cited by 47
Therapeutic Perspectives on the Modulation of G-Protein Coupled Estrogen Receptor, GPER, Function
Rouhimoghadam, M., Lu, A. S., Salem, A. K., & Filardo, E. J. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.591217 · Cited by 49
AKT Blocks SIK1-Mediated Repression of STAT3 to Promote Breast Tumorigenesis
Sun, Z., Jiang, Q., Gao, B. X., Zhang, X., Bu, L., Wang, L., Lin, Y., Xie, W., Li, J., & Guo, J. (2023) · Cancer Research · doi:10.1158/0008-5472.can-22-3407 · Cited by 45
Targeting the RAS upstream and downstream signaling pathway for cancer treatment
Hossain, M. A. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.176727 · Cited by 51
Font-Díaz, J., Jiménez‐Panizo, A., Caelles, C., Vivanco, M. D., Pérez, P., Aranda, A., Estébanez‐Perpiñá, E., Castrillo, A., Ricote, M., & Valledor, A. F. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.12.007 · Cited by 45
Anti-Cancer Potency of Copper-Doped Carbon Quantum Dots Against Breast Cancer Progression
Wang, M., Lan, S., Zhang, W., Jin, Q., Du, H., Sun, X., He, L., Meng, X., Su, L., & Liu, G. (2024) · International Journal of Nanomedicine · doi:10.2147/ijn.s449887 · Cited by 44
Quinazolinones as Potential Anticancer Agents: Synthesis and Action Mechanisms
Deng, Z., Li, J., Zhu, P., Wang, J., Kong, Y., Hu, Y., Cai, J., & Dong, C. (2025) · Biomolecules · doi:10.3390/biom15020210 · Cited by 46
PI3K Driver Mutations: A Biophysical Membrane-Centric Perspective
Zhang, M., Jang, H., & Nussinov, R. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-0911 · Cited by 42
Sea Cucumber Intestinal Peptide Induces the Apoptosis of MCF-7 Cells by Inhibiting PI3K/AKT Pathway
Wei, W., Fan, X.-M., Jia, S., Zhang, X., Zhang, Z., Zhang, X.-J., Zhang, J.-X., & Zhang, Y. (2021) · Frontiers in Nutrition · doi:10.3389/fnut.2021.763692 · Cited by 48
Targeting Signaling Pathway Networks in Several Malignant Tumors: Progresses and Challenges
He, H., Shao, X., Li, Y., Gihu, R., Xie, H., Zhou, J., & Yan, H. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.675675 · Cited by 41
Gao, L., Nie, X., Gou, R., Hu, Y., Dong, H., Li, X., & Lin, B. (2021) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.16983 · Cited by 39
Alpelisib in the Treatment of Breast Cancer: A Short Review on the Emerging Clinical Data
Armaghani, A. J., & Han, H. S. (2020) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s219436 · Cited by 38
Molecular perspective on targeted therapy in breast cancer: a review of current status
Cetinkaya, B. D., & Avcı, Ç. B. (2022) · Medical Oncology · doi:10.1007/s12032-022-01749-1 · Cited by 39
Immune Checkpoint Inhibitors and Novel Immunotherapy Approaches for Breast Cancer
Solís, M. C., Vethencourt, A., & Pernas, S. (2022) · Current Oncology Reports · doi:10.1007/s11912-022-01339-4 · Cited by 38
PI3KCA Mutations in Uterine Cervix Carcinoma
Voutsadakis, I. A. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10020220 · Cited by 35
Dunn, S., Eberlein, C., Yu, J., Gris‐Oliver, A., Ong, S. H., Yelland, U., Cureton, N., Staniszewska, A. D., McEwen, R. K., Fox, M., et al. (2022) · Oncogene · doi:10.1038/s41388-022-02482-9 · Cited by 37
Characterizations of Cancer Gene Mutations in Chinese Metastatic Breast Cancer Patients
Tao, Z., Li, T., Feng, Z., Liu, C., Shao, Y., Zhu, M., Gong, C., Wang, B., Cao, J., Wang, L., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01023 · Cited by 36
Role of RhoC in cancer cell migration
Lou, Y., Jiang, Y., Liang, Z., Liu, B., Li, T. X., & Zhang, D. (2021) · Cancer Cell International · doi:10.1186/s12935-021-02234-x · Cited by 38
Sharma, P. P., Khan, M. A., Najmi, A. K., Chaturvedi, S., & Akhtar, M. (2022) · Medical Oncology · doi:10.1007/s12032-022-01856-z · Cited by 34
Wylaź, M., Kaczmarska, A., Pajor, D., Hryniewicki, M., Gil, D., & Dulińska-Litewka, J. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115676 · Cited by 37
Biological effects and regulation of IGFBP5 in breast cancer
Dittmer, J. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.983793 · Cited by 32
Hou, Y., Pi, C., Feng, X., Wang, Y., Fu, S., Zhang, X., Zhao, L., & Wei, Y. (2020) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2020.08.018 · Cited by 29
Naeem, M., Iqbal, M. O., Khan, H., Ahmed, M. M., Farooq, M., Aadil, M. M., Jamaludin, M. I., Hazafa, A., & Tsai, W.-C. (2022) · Molecules · doi:10.3390/molecules27113412 · Cited by 29
Liu, L., Graff, S. L., & Wang, Y. (2024) · Cancers · doi:10.3390/cancers17010016 · Cited by 29
Targeting PI3K inhibitor resistance in breast cancer with metabolic drugs
Gremke, N., Besong, I., Stroh, A., von Wichert, L., Witt, M., Elmshäuser, S., Wanzel, M., Fromm, M. F., Taudte, R. V., Schmatloch, S., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02180-4 · Cited by 31
Research update on the anticancer effects of buparlisib (Review)
Xing, J., Yang, J. H., Gu, Y., & Yi, J. (2021) · Oncology Letters · doi:10.3892/ol.2021.12527 · Cited by 27
Lee, Y., Cherng, Y., Yang, S., Liu, S., Chen, T.-L., & Chen, R. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/5558618 · Cited by 28
Labrèche, C., Cook, D. P., Abou‐Hamad, J., Pascoal, J., Pryce, B. R., Al‐Zahrani, K. N., & Sabourin, L. A. (2021) · Breast Cancer Research · doi:10.1186/s13058-021-01487-8 · Cited by 26
Tandem Suzuki Coupling/Intramolecular Oxetane Ring Opening to Form Polycyclic Ring Systems
DeRatt, L. G., Lawson, E. C., Kumar., K., V, Hwang, S. S., DesJarlais, R. L., & Kuduk, S. D. (2020) · Organic Letters · doi:10.1021/acs.orglett.0c01899 · Cited by 27
Targeting PI3K signaling in Lung Cancer: advances, challenges and therapeutic opportunities
Zhang, B., Leung, P., Cho, W. C. S., Wong, C. K., & Wang, D. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06144-8 · Cited by 26
Effect of Oxaliplatin, Olaparib and LY294002 in Combination on Triple-Negative Breast Cancer Cells
Andreidesz, K., Kőszegi, B., Kovács, D., Vántus, V. B., Gallyas, F., & Kovács, K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22042056 · Cited by 26
Zhang, S., Li, M., Qiu, Y., Wu, J., Xu, X., Ma, Q., Zheng, Z., Lu, G., Deng, Z., & Huang, H. (2023) · Glia · doi:10.1002/glia.24491 · Cited by 26
Histopathologic, Genetic and Molecular Characterization of Endometrial Cancer Racial Disparity
Javadian, P., Washington, C. R., Mukasa, S., & Benbrook, D. M. (2021) · Cancers · doi:10.3390/cancers13081900 · Cited by 24
Ye, Y., Huang, Z., Zhang, M., Li, J., Zhang, Y., & Lou, C. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.114183 · Cited by 27
Targeting HDACs for diffuse large B-cell lymphoma therapy
Wu, C., Song, Q., Gao, S. W., & Wu, S.-L. (2024) · Scientific Reports · doi:10.1038/s41598-023-50956-x · Cited by 21
Kwon, H. W., Lee, J. H., Pahk, K., Park, K. H., & Kim, S. (2021) · Cancer Imaging · doi:10.1186/s40644-021-00424-4 · Cited by 22
Khoshdel, F., Mottaghi-Dastjerdi, N., Yazdani, F., Salehi, S., Ghorbani, A., Montazeri, H., Soltany‐Rezaee‐Rad, M., & Goodarzy, B. (2024) · Discover Oncology · doi:10.1007/s12672-024-01225-4 · Cited by 20
Leenhardt, F., Alexandre, M., & Jacot, W. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1873952 · Cited by 21
Mishra, R., Yuan, L., Patel, H. M., Karve, A. S., Zhu, H., White, A., Alanazi, S., Desai, P. B., Merino, E. J., & Garrett, J. T. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22042088 · Cited by 20
Growth Hormone Modulation of Hepatic Epidermal Growth Factor Receptor Signaling
González, L., Díaz, M. E., Miquet, J. G., Sotelo, A. I., & Dominici, F. P. (2021) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2021.03.004 · Cited by 20
In vitro breast cancer models for studying mechanisms of resistance to endocrine therapy
Cheng, G. J., Leung, E. Y., & Singleton, D. C. (2022) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2022.00084 · Cited by 22
Curcumol inhibits breast cancer growth via NCL/ERα36 and the PI3K/AKT pathway
Zhou, W., Juan, W., tong, D., Juan, L. X., Yi, L., Huang, J., Guan, X., Xiang, L. G., Jie, H. M., & Chen, X. (2022) · Food & Function · doi:10.1039/d2fo02387c · Cited by 20
Synergistic actions of Alpelisib and Melatonin in breast cancer cell lines with PIK3CA gene mutation
de Godoy, B. L. V., Moschetta‐Pinheiro, M. G., Chuffa, L. G. D. A., Ponde, N. F., Reiter, R. J., Colombo, J., & Zuccari, D. A. P. D. C. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.121708 · Cited by 20
A bi-steric mTORC1-selective inhibitor overcomes drug resistance in breast cancer
Meng, D., Zhao, X., Yang, Y. C., Navickas, A., Helland, C., Goodarzi, H., Singh, M., & Bandyopadhyay, S. (2023) · Oncogene · doi:10.1038/s41388-023-02737-z · Cited by 21
The mechanism of AKT activation in cancer
Meng, F., Li, H., Wang, Y., Zheng, Z., & Chen, Y. (2025) · Cell investigation. · doi:10.1016/j.clnves.2025.100046 · Cited by 18
Soong, T. R., Dillon, D. A. R., Rice-Stitt, T. L., Wieczorek, T. J., Baker, G. M., Darvishian, F., Collins, L. C., Lester, S. C., Schnitt, S. J., & Harrison, B. T. (2022) · Modern Pathology · doi:10.1038/s41379-022-01084-w · Cited by 19
The prognostic significance of tumor-infiltrating lymphocytes in cervical cancer
He, M., Wang, Y., Zhang, G., Cao, K., Yang, M., & Liu, H. (2021) · Journal of Gynecologic Oncology · doi:10.3802/jgo.2021.32.e32 · Cited by 19
Wang, T., Dong, J., Xu, Y., Wen, H., Wu, L., Liu, J., Sui, H. X., & Deng, W. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.653306 · Cited by 19
Immunosuppressive Signaling Pathways as Targeted Cancer Therapies
Damane, B. P., Hull, R., Bida, M., Durandt, C., Mulaudzi, T. V., Chatziioannou, A. A., & Dlamini, Z. (2022) · Biomedicines · doi:10.3390/biomedicines10030682 · Cited by 20
Regulation of mRNA Translation by Hormone Receptors in Breast and Prostate Cancer
Xie, J., Kusnadi, E. P., Furic, L., & Selth, L. A. (2021) · Cancers · doi:10.3390/cancers13133254 · Cited by 18
Wang, Y., Liu, Y., Ge, T., Tang, J., Wang, S., Gao, Z., Chen, J., Xu, J., Gong, P., Zhao, Y., et al. (2022) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2022.106211 · Cited by 18
HER2-Positive Breast Cancer Treatment and Resistance
Veeraraghavan, J., Angelis, C. D., Gutiérrez, C., Liao, F.-T., Sabotta, C. M., Rimawi, M. F., Osborne, C. K., & Schiff, R. (2025) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-70875-6_24 · Cited by 21
Development of PI3Kα inhibitors for tumor therapy
Jia, W., Luo, S., Guo, H. W., & Kong, D. (2022) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2022.2132293 · Cited by 20
Dubey, R., Sharma, A., Gupta, S., Gupta, G. D., & Asati, V. (2023) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2023.107077 · Cited by 18
PAM (PIK3/AKT/mTOR) signaling in glia: potential contributions to brain tumors in aging
Duggan, M. R., Weaver, M. W., & Khalili, K. (2021) · Aging · doi:10.18632/aging.202459 · Cited by 16
Luo, W., Han, Y., Li, X., Liu, Z., Meng, P., & Wang, Y. (2022) · Genetics Research · doi:10.1155/2022/2249909 · Cited by 16
PIK3CAMutations in Breast Cancer Subtypes Other Than HR-Positive/HER2-Negative
Ascione, L., Zagami, P., Nicolò, E., Crimini, E., Curigliano, G., & Criscitiello, C. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12111793 · Cited by 16
Abemaciclib: safety and effectiveness of a unique cyclin-dependent kinase inhibitor
Gebbia, V., Valerio, M. R., Firenze, A., & Vigneri, P. G. (2020) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2020.1781814 · Cited by 16
Combined endocrine and targeted therapy in luminal breast cancer
Cesca, M. G., Pandolfi, N. C., Maciel, D., Lima, J., Sanches, S. M., & Ponde, N. F. (2021) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2021.1960160 · Cited by 16
Nuclear Mechanisms Involved in Endocrine Resistance
Dittmer, J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.736597 · Cited by 16
Liquid Biopsy as a Diagnostic and Prognostic Tool for Women and Female Dogs with Breast Cancer
Colombo, J., Moschetta‐Pinheiro, M. G., Novais, A. A., Stoppe, B. R., Bonini, E. D., Gonçalves, F. M., Fukumasu, H., Coutinho, L. L., Chuffa, L. G. D. A., & Zuccari, D. A. P. D. C. (2021) · Cancers · doi:10.3390/cancers13205233 · Cited by 16
ELK1 / KIFC1 axis promotes breast cancer cell proliferation by regulating glutathione metabolism
Yang, B., Wang, H., Jian, X., Chen, W., & Chen, W. (2023) · Journal of obstetrics and gynaecology research · doi:10.1111/jog.15710 · Cited by 16
Yang, L., Zhao, S., Zhu, T., & Zhang, J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.624493 · Cited by 15
Yuan, J., Duan, F., Zhai, W., Song, C., Wang, L., Xia, W., Hua, X., Yuan, Z., Bi, X., & Huang, J. (2021) · International Journal of Women s Health · doi:10.2147/ijwh.s334756 · Cited by 14
Eapen, J. V., George, P. R., Thomas, S., & Antony, J. (2025) · ASPET Discovery · doi:10.1016/j.aspetd.2025.100012 · Cited by 14
Kang, S. Y., Lee, E. J., Byun, J. W., Han, D., Choi, Y., Hwang, D. W., & Lee, D. S. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.785450 · Cited by 14
Metadata
- Authors
- Verret, B., Cortes, J., Bachelot, T., Andre, F., & Arnedos, M.
- Affiliations
- Institut Gustave Roussy (FR)
- Centre Léon Bérard (FR)
- Inserm (FR)
- Corresponding author
- Arnedos, M.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2019-12
- Volume
- 30
- Issue
- Suppl_10
- Pages
- x12-x20
- ISSN
- 0923-7534 (ISSN-L)
- PMC
- PMC6923787
- OpenAlex
- W2996642785
- Cited by
- 221
- References
- 102
- Citations by year
- 2026: 10 · 2025: 24 · 2024: 44 · 2023: 31 · 2022: 38 · 2021: 48 · 2020: 26
- FWCI
- 2.47
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Annals of Oncology (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- Novartis
- AstraZeneca
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Keywords
- PI3K inhibitors, PI3K/Akt signaling, advanced breast cancer, alpelisib, PIK3CA mutation, endocrine therapy resistance, hormone receptor-positive breast cancer, fulvestrant, combination therapy, drug toxicity
- MeSH terms
- Phosphoinositide-3 Kinase Inhibitors, Animals, Breast Neoplasms, Female, Humans, Signal Transduction, Randomized Controlled Trials as Topic, Phosphatidylinositol 3-Kinases, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
